Homology Medicines Past Earnings Performance
Past criteria checks 0/6
Homology Medicines has been growing earnings at an average annual rate of 2.2%, while the Biotechs industry saw earnings growing at 14.5% annually. Revenues have been growing at an average rate of 2.1% per year.
Key information
2.2%
Earnings growth rate
13.0%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | 2.1% |
| Return on equity | -154.8% |
| Net Margin | -9,771.7% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
Homology Medicines (NASDAQ:FIXX) Will Have To Spend Its Cash Wisely
Nov 16
Homology Medicines appoints new CEO, chairperson
Sep 06Homology announces peer-reviewed preclinical data publication on its AAVHSC16 capsid
Jul 05Here's Why We're Watching Homology Medicines' (NASDAQ:FIXX) Cash Burn Situation
Jan 28Homology Medicines: In Vivo Gene Therapy Platform With Delayed Lead Trial Coming Back Online
Oct 22We Think Homology Medicines (NASDAQ:FIXX) Can Afford To Drive Business Growth
Sep 18Growth Investors: Industry Analysts Just Upgraded Their Homology Medicines, Inc. (NASDAQ:FIXX) Revenue Forecasts By 20%
Aug 14Industry Analysts Just Made A Sizeable Upgrade To Their Homology Medicines, Inc. (NASDAQ:FIXX) Revenue Forecasts
May 22Homology Medicines (FIXX) Investor Presentation - Slideshow
May 05Homology Medicines (NASDAQ:FIXX) Is In A Good Position To Deliver On Growth Plans
Apr 17Are Institutions Heavily Invested In Homology Medicines, Inc.'s (NASDAQ:FIXX) Shares?
Mar 13Homology Medicines' (NASDAQ:FIXX) Stock Price Has Reduced 25% In The Past Year
Feb 03Revenue & Expenses BreakdownBeta
How Homology Medicines makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 1 | -113 | 30 | 0 |
| 30 Sep 23 | 2 | -131 | 32 | 0 |
| 30 Jun 23 | 3 | -132 | 32 | 0 |
| 31 Mar 23 | 3 | -126 | 32 | 0 |
| 31 Dec 22 | 3 | -5 | 38 | 0 |
| 30 Sep 22 | 3 | -4 | 41 | 0 |
| 30 Jun 22 | 4 | -1 | 41 | 0 |
| 31 Mar 22 | 5 | -3 | 42 | 0 |
| 31 Dec 21 | 34 | -96 | 37 | 0 |
| 30 Sep 21 | 34 | -92 | 34 | 0 |
| 30 Jun 21 | 33 | -90 | 34 | 0 |
| 31 Mar 21 | 31 | -94 | 33 | 0 |
| 31 Dec 20 | 3 | -129 | 33 | 0 |
| 30 Sep 20 | 2 | -123 | 31 | 0 |
| 30 Jun 20 | 2 | -124 | 28 | 0 |
| 31 Mar 20 | 2 | -115 | 25 | 0 |
| 31 Dec 19 | 2 | -104 | 22 | 0 |
| 30 Sep 19 | 2 | -99 | 22 | 0 |
| 30 Jun 19 | 3 | -83 | 19 | 0 |
| 31 Mar 19 | 4 | -69 | 18 | 0 |
| 31 Dec 18 | 5 | -56 | 17 | 0 |
| 30 Sep 18 | 4 | -49 | 15 | 0 |
| 30 Jun 18 | 3 | -41 | 13 | 0 |
| 31 Mar 18 | 1 | -35 | 10 | 0 |
| 31 Dec 17 | 0 | -30 | 8 | 0 |
Quality Earnings: FIXX is currently unprofitable.
Growing Profit Margin: FIXX is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: FIXX is unprofitable, but has reduced losses over the past 5 years at a rate of 2.2% per year.
Accelerating Growth: Unable to compare FIXX's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: FIXX is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-8.9%).
Return on Equity
High ROE: FIXX has a negative Return on Equity (-154.76%), as it is currently unprofitable.